BlossomHill Therapeutics, Inc. cash flow to debt ratio of -209.51% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

BlossomHill Therapeutics, Inc.'s free cash flow has decreased 52.32% from $-31.51M last year to $-47.99M, signaling decreasing performance

BlossomHill Therapeutics, Inc.'s debt to equity ratio is 0.28, which means that the company's assets are healthy financed, signaling financial stability.

BlossomHill Therapeutics, Inc.'s debt has increased relative to shareholder equity from -0.01 last year to 0.28 today, signaling weakened financials

BlossomHill Therapeutics, Inc. has a net cash position, so leverage is healthy.

BlossomHill Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

BlossomHill Therapeutics, Inc. has insufficient data to evaluate this check.

BlossomHill Therapeutics, Inc.'s short-term assets of $138.83M exceed its short-term liabilities of $15.48M

BlossomHill Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

BlossomHill Therapeutics, Inc.'s return on equity of 127.76%, is higher than 15.00%, indicating good performance

BlossomHill Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

BlossomHill Therapeutics, Inc. has insufficient public price history to evaluate earnings stability.

BlossomHill Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

BlossomHill Therapeutics, Inc. has negative free cash flow, indicating cash burn

BlossomHill Therapeutics, Inc.'s yearly earnings has decreased 97.28% since last year from $-30.70M to $-60.55M, signaling decreasing performance

BlossomHill Therapeutics, Inc. has insufficient data to evaluate this check.

ROIC -43.86% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

BlossomHill Therapeutics, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

BlossomHill Therapeutics, Inc. has insufficient public price history to evaluate revenue consistency.

BlossomHill Therapeutics, Inc. has insufficient public price history to evaluate ROE consistency.

BlossomHill Therapeutics, Inc. has insufficient data to evaluate this check.

BlossomHill Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

BlossomHill Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on Base EBITDA Valuation model

BlossomHill Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

BlossomHill Therapeutics, Inc. has insufficient data to evaluate this check.

BlossomHill Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

BlossomHill Therapeutics, Inc. has a price-to-book ratio of 6.53x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

BlossomHill Therapeutics, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue